2021 Psychedelic Investor Guide Released
Ryan Allway
October 20th, 2021
Psychedelics, Top News
MIAMI, Oct. 20, 2021 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its wholly owned KetaDASH will be one of the sponsors of the 2021 Psychedelic Investor Guide. KetaDASH is an Intravenous (IV) based, home delivery platform for patients who have been prescribed Ketamine.
“Sponsoring the Psychedelic Investor Guide is a great opportunity for Ehave as we roll out our KetaDASH platform and home infusion service,” said Ben Kaplan, CEO of Ehave. “We want to let the psychedelic industry know more about KetaDASH, which additionally is a HIPAA compliant, cloud-based patient monitoring platform that will be early to market as one of the first home healthcare providers offering IV based infusion therapy of ketamine.”
Using the intuitive HIPAA compliant KetaDash cloud-based app, patients can find the best facilities to have treatment prescribed, and once prescribed check the availability of nurses. During and after treatment, the app can monitor the treatment allowing patients and medical professionals to view detailed reports on the ketamine therapy’s progress.
Institutional Analyst Inc. announced the release of the 2021 Psychedelic Investor Guide on Monday, October 18th. The Psychedelic Investor Guide is the most comprehensive and easy to use guide covering the rapidly growing Psychedelic investment landscape.
Forty-six of the leading companies in the sector are listed.
Each Profile Contains:
- Stock chart
- Financial information
- Business description
- Six of the most recent headlines, with links to company press releases.
Additionally included are direct links to each Company’s investor relations page and a direct link to their SEC or SEDAR filings pages. The Guide provides everything an investor needs, to get acquainted with the emerging leaders.
The Guide Features:
Large cap companies over $500 million such as Atai Life Sciences $ATAI ($2 billion), Compass Pathways $CMPS ($1.3 billion) and Mind Medicine $MNMD ($870 million).
7 mid-cap companies valued over $100 million.
29 small-cap companies valued under $100 million such as Bright Minds Biosciences $BMBIF ($88 million), Small Pharma $DMTTF ($70 million) and Mydecine Group $MYCOF ($66 million).
12 micro-cap companies under $25 million such as Wesana Health $WSNAF ($25 million), BetterLife Pharma BETRF ($20 million) and Delic Holding $DELCF ($11 million).
“We created the Guide in a readable PDF format which provides an easy and quick way for investors to literally flip page after page, looking for investment opportunities,” stated Roland Rick Perry, editor of the Psychedelic Stock Review. “If an investor is seriously hunting for new ideas, this can save hours and hours of tedious research work. It took our team weeks to gather the data and present it in the easiest and most readable format available, in magazine style – which can be printed.”
Everything an investor needs to get started, is right at the touch of their fingertips. Reviewing the Guide is less time consuming than clicking on site after site, and webpage after webpage in the research gathering process.
The guide will be updated monthly, and the company list updated weekly on our website under the A-Z Universe section of the website. The Guide will be renamed the 2022 Investor Guide on January 4th. Additions and deletions to the list will occur as warranted by its research staff.
To receive your free copy of the 2021 Psychedelic Investor guide visit http://psychedelicstockreview.com/2021-psychedelic-investor-guide/
The Guide will be delivered directly to the 20,000 subscribers of the Biotech Stock Review, with no need to resubscribe.
Copies will additionally be printed and mailed to Analysts and Investment Bankers providing psychedelic sector coverage at Aegis, Baader Bank, Berenberg Capital, Bloom Burton, Canaccord, Cantor Fitzgerald, CITI Investment Research, Clarus, Cowen, Credit Suisse, Dejardins Securities, HC Wainwright, Maxim, RBC Capital, Roth Capital, Stifel GMP and Think Equity. As well as to our proprietary database of small-cap Biotech Investment Bankers and Biotech Hedge Funds.
About Institutional Analyst
Institutional Analyst was launched in 1995 as an independent research and investor‐relations-consulting firm that publishes investment grade research reports on independently selected companies. Institutional Analyst Inc., manages several industry specific websites and newsletters including the Internet Stock Review, the Biotech Stock Review, the Marijuana Stock Review and Beverage Start Up News. The firm is additionally retained to create broad-based industry guides, by professional investors such as hedge funds, for newly emerging sectors including the Psychedelic sector.
For further information, publicly traded Companies can contact Roland Perry at 310-594-8062 or Roland@InstitutionalAnalyst.com
About Ehave, Inc.
Qualified patients, doctors, and clinics are invited to visit http://www.KetaDash.com/sign-up for more information.
Ehave, Inc. (EHVVF) is a leader of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. Our main product is the Ehave Telemetry Portal, which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.
Additional Sponsors
New to the Street TV
The 2021 Guide is sponsored in part by New to the Street, which since 2009 produces biographical investment related interviews, across major U.S. Television networks. The TV platforms include NewsMax, reaches over 540 million homes in aggregate every Sunday. New to the Street will publicize the Guides availability to this audience.
Companies interested in appearing in our upcoming Psychedelic Investor TV episode are invited to visit http://psychedelicstockreview.com/psychedelic-investor-tv/
or call Roland Perry at 310-594-8062
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Amercanex was founded with the sole-purpose to ensure a completely transparent, neutral, and non-manipulated marketplace for cannabis industry participants.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
